The Male Infertility drugs in development market research report provides comprehensive information on the therapeutics under development for Male Infertility, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Male Infertility. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Male Infertility and features dormant and discontinued products.

GlobalData tracks 17 drugs in development for Male Infertility by 16 companies/universities/institutes. The top development phase for Male Infertility is preclinical with six drugs in that stage. The Male Infertility pipeline has 13 drugs in development by companies and four by universities/ institutes. Some of the companies in the Male Infertility pipeline products market are: Ferring International Center, Ben-Gurion University of the Negev and University of Bonn.

The key targets in the Male Infertility pipeline products market include Follicle Stimulating Hormone Receptor (Follitropin Receptor or FSHR), Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC, and Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11).

The key mechanisms of action in the Male Infertility pipeline product include Follicle Stimulating Hormone Receptor (Follitropin Receptor or FSHR) Agonist with five drugs in Phase II. The Male Infertility pipeline products include three routes of administration with the top ROA being Oral and eight key molecule types in the Male Infertility pipeline products market including Small Molecule, and Recombinant Protein.

Male Infertility overview

Male infertility refers to a male’s inability to achieve a pregnancy in a fertile female. Male infertility is caused by low sperm production, immobile sperm, or blockages that prevent the delivery of sperm. Symptoms include pain, swelling, or a lump in the testicle area. Predisposing factors include smoking, alcohol use, overweight, toxin exposure, and certain medical conditions including tumors and chronic illnesses. Treatment includes surgery and hormone replacement therapy.

For a complete picture of Male Infertility’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.